VRAX
Virax Biolabs Group Limited
NasdaqCMUSDEQUITY
DELAYED
Strong sell
-80/100
Last price
1.97
▼ 0.43 (17.92%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.40
Prev close
2.40
Day high
2.33
Day low
1.85
Volume
310.73K
Market cap
—
P/E (TTM)
—
52W range
1.85 – 21.75
Day trading desk
Gap from prior close
+0.20%
Prior close 2.40
VWAP
2.05
-4.09% from price
Relative volume
—
—
Session range
34.59%
1.85 – 2.49
Position in range
19%
Near session low
ATR (14D)
0.30
15.25% of price
Prior day high
3.34
PDH
Prior day low
2.16
PDL
Bid / ask spread
—
Quote not published
Session volume
610.95K
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-8.97%
-10.9%
1M
-22.67%
-23.8%
3M
-36.16%
-40.7%
6M
-42.00%
-60.2%
YTD
-76.53%
-90.8%
1Y
-86.82%
-103.2%
3Y
-97.50%
-179.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on VRAX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $12.42K | $6.33K | $156.42K | $8.56K | +96.2% |
| Operating revenue | $12.42K | $6.33K | $156.42K | $8.56K | +96.2% |
| Cost of revenue | $4.73K | $59.40K | $105.83K | $9.93K | -92.0% |
| Gross profit | $7.69K | -$53.07K | $50.59K | -$1.36K | +114.5% |
| Research & development | $3.74M | $2.03M | $1.61M | $2.18M | +84.0% |
| Selling, general & admin | $2.67M | $3.99M | $4.57M | $3.55M | -33.1% |
| Total operating expense | $6.41M | $6.02M | $6.19M | $5.73M | +6.4% |
| Operating income | -$6.40M | -$6.08M | -$6.14M | -$5.73M | -5.3% |
| Net interest income | -$61.77K | -$58.18K | -$26.88K | -$15.47K | -6.2% |
| Pre-tax income | -$5.93M | -$6.20M | -$6.74M | -$5.46M | +4.4% |
| Tax provision | -$900.24K | -$136.66K | $0 | $0 | -558.7% |
| Net income | -$5.02M | -$6.06M | -$6.73M | -$5.46M | +17.1% |
| Net income to common | -$5.02M | -$6.06M | -$6.73M | -$5.46M | +17.1% |
| Basic EPS | -12.64 | -40.62 | -83.90 | -128.25 | +68.9% |
| Diluted EPS | -12.64 | -40.62 | -83.90 | -128.25 | +68.9% |
| EBIT | -$5.87M | -$6.15M | -$6.71M | -$5.44M | +4.5% |
| EBITDA | -$5.43M | -$5.80M | -$6.61M | -$5.44M | +6.4% |
| Basic shares | 397.59K | 149.21K | 80.26K | 42.52K | +166.5% |
| Diluted shares | 397.59K | 149.21K | 80.26K | 42.52K | +166.5% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.44M | $4.23M | $3.59M | $9.35M | — | +52.3% |
| Cash & short-term investments | $6.44M | $4.23M | $3.59M | $9.35M | — | +52.3% |
| Accounts receivable | — | — | — | — | $0 | — |
| Inventory | $0 | $94.67K | $60.38K | $0 | — | -100.0% |
| Total current assets | $6.83M | $4.89M | $4.38M | $9.63M | — | +39.5% |
| Property, plant & equipment | $1.50M | $1.53M | $1.10M | $0 | — | -2.4% |
| Goodwill & intangibles | — | — | $0 | $178.40K | $0 | — |
| Total assets | $8.32M | $6.43M | $5.48M | $9.81M | — | +29.5% |
| Total current liabilities | $685.02K | $673.21K | $168.85K | $908.40K | — | +1.8% |
| Current debt | $28.48K | $32.47K | — | $146.25K | — | -12.3% |
| Total debt | $414.39K | $377.00K | $224.30K | $146.25K | — | +9.9% |
| Total liabilities | $989.83K | $964.75K | $345.19K | $908.40K | — | +2.6% |
| Retained earnings | -$29.61M | -$24.59M | -$18.53M | -$11.79M | — | -20.4% |
| Shareholder equity | $7.58M | $5.70M | $5.37M | $9.13M | — | +33.0% |
| Working capital | $6.14M | $4.22M | $4.21M | $8.73M | — | +45.6% |
| Net tangible assets | $7.58M | $5.70M | $5.37M | $8.95M | — | +33.0% |
| Shares issued | 579.22K | 173.68K | 102.96K | 62.19K | — | +233.5% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$5.03M | -$6.07M | -$6.74M | -$5.46M | +17.1% |
| Depreciation & amortisation | $439.02K | $343.39K | $103.10K | $0 | +27.8% |
| Stock-based compensation | $130.41K | $365.31K | $1.01M | $1.73M | -64.3% |
| Change in working capital | $258.73K | $625.62K | -$1.27M | -$182.33K | -58.6% |
| Operating cash flow | -$4.62M | -$4.56M | -$6.40M | -$4.18M | -1.3% |
| Capital expenditure | -$255.83K | -$603.89K | -$1.16M | -$178.40K | +57.6% |
| Investing cash flow | -$255.83K | -$603.89K | -$1.16M | -$178.40K | +57.6% |
| Financing cash flow | $7.09M | $5.81M | $1.80M | $13.69M | +22.1% |
| Free cash flow | -$4.88M | -$5.17M | -$7.56M | -$4.36M | +5.6% |
| End cash position | $6.44M | $4.23M | $3.59M | $9.35M | +52.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $6.44M | $3.35M | $4.23M | +92.5% |
| Cash & short-term investments | $6.44M | $3.35M | $4.23M | +92.5% |
| Accounts receivable | — | $729 | — | — |
| Inventory | $0 | $54.19K | $94.67K | -100.0% |
| Total current assets | $6.83M | $4.15M | $4.89M | +64.6% |
| Property, plant & equipment | $1.50M | $1.57M | $1.53M | -4.4% |
| Total assets | $8.32M | $5.72M | $6.43M | +45.7% |
| Total current liabilities | $685.02K | $365.47K | $673.21K | +87.4% |
| Current debt | $28.48K | $195.58K | $32.47K | -85.4% |
| Total debt | $414.39K | $537.99K | $377.00K | -23.0% |
| Total liabilities | $989.83K | $641.52K | $964.75K | +54.3% |
| Retained earnings | -$29.61M | -$26.93M | -$24.59M | -10.0% |
| Shareholder equity | $7.58M | $5.31M | $5.70M | +42.6% |
| Working capital | $6.14M | $3.78M | $4.22M | +62.4% |
| Net tangible assets | $7.58M | $5.31M | $5.70M | +42.6% |
| Shares issued | 579.22K | 261.74K | 173.68K | +121.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.30
-14.28% from price
SMA 20
2.44
-16.81% from price
SMA 50
2.69
-24.50% from price
SMA 100
3.55
-44.51% from price
SMA 200
4.60
-55.85% from price
EMA 12
2.31
-14.76% from price
EMA 26
2.48
-20.53% from price
EMA 50
2.76
-28.50% from price
RSI (14)
35.5
Neutral
MACD (12,26,9)
-0.17
Hist -0.01
ATR (14)
0.30
14.80% of price
Realised vol 30D
81.3%
Annualised
Bollinger upper
2.84
20, 2σ
Bollinger lower
2.04
20, 2σ
50 / 200 cross
Death
2.69 vs 4.60
Trend bias
Below 200
-55.85%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.06
More volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
81.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-88.2%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.30
14.80% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Join Virax's Live Investor Webinar: Advancing Immune Diagnostics, Clinical Development and Commercial Execution
ACCESS Newswire · 48d ago
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
ACCESS Newswire · 61d ago
Alliance Entertainment and Virax Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ACCESS Newswire · 79d ago
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
PR Newswire · 83d ago
Virax Biolabs enters immune profiling product supply deal with Fosun
Medical Device Network · 86d ago
Virax Biolabs enters immune profiling product supply deal with Fosun
Hospital Management · 86d ago
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
PR Newswire · 88d ago
Top Premarket Decliners
MT Newswires · 89d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.